TABLE 2.

Clinical trials on pulmonary surfactants for the treatment of ARDS in COVID-19 patients.

Surfactant	Dose	Administration route	Study type	Primary purpose	NCT number
Poractant alfa	50 mg/kg only once	Bronchial fibroscopy	Interventional	Treatment using Curosurf® in adult acute respiratory distress syndrome due to COVID-19	NCT04384731
Poractant alfa	30 mg/kg once a day for 3 days	Endotracheal intubation	Interventional	Treatment using poractant alfa - curosurf for SARS-cov-19 ARDS (Covid-19)	NCT04502433
Bovine lung extract surfactant	50 mg/kg once a day for 3 days	Endotracheal intubation	Interventional	Treatment using London’s exogenous surfactant study for COVID-19 (LESSCOVID)	NCT04375735
Bovine lung extract surfactant	150 mg twice a day for 5 days	Inhalation	Observational	Treatment using Surfactant-BL in adult ARDS due to COVID-19	NCT04568018
Lucinactant	80 mg	Injection	Interventional	Treatment by assessing the safety and preliminary tolerability of lyophilized lucinactant in adults with Covid-19	NCT04389671
COVSurf	N/A	N/A	Interventional	Treatment using delivery of the surfactant to the lungs	NCT04362059
Exogenous surfactant		Inhalation	Interventional	Evaluation of the effect of exogenous surfactant through nebulizer mask on clinical outcomes in Covid-19 patients	NCT04847375
Biological: AT-100 (rhSP-D)	75 or 150 mg once a day for 7 days	Intratracheal administration	Interventional	Treatment: Safety study on AT-100 in treating adults with severe COVID-19 infection	NCT04659122

Note: N/A, Not applicable; ARDS, Acute Respiratory Distress Syndrome; NCT, National Clinical Trials.